Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-08049820 dose-ranging study in moderate to severe atopic dermatitis
2025-522965-31-00Phase 2Authorised
- Sponsor
- Pfizer
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 2, randomised, double-blind trial in atopic dermatitis (AD) comparing PF-08049820 with Placebo (2 arms). Primary endpoint: Percent change from baseline in EASI total score at Week 12. Planned start Oct 2026; status: authorised.
02
Drugs
PF-08049820
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2025-522965-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522965-31-00.